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AbsTrACT
Objectives Despite many shared risk factors and 
pathophysiological pathways, the risk of ischaemic heart 
disease (ihD) and myocardial infarction (Mi) in interstitial 
lung disease (ilD) remains poorly understood. This lack 
of data could be preventing patients who may benefit 
from screening for these cardiovascular diseases from 
receiving it.
Methods a population- based cohort study used 
electronic patient records from the clinical Practice 
research Datalink and linked hospital episode statistics 
to identify 68 572 patients (11 688 ilD exposed (mean 
follow- up: 3.8 years); 56 884 unexposed controls (mean 
follow- up: 4.0 years), with 349 067 person- years of 
follow- up. ilD- exposed patients (pulmonary sarcoidosis 
(Ps) or idiopathic pulmonary fibrosis (PF)) were matched 
(by age, sex, registered general practice and available 
follow- up time) to patients without ilD or ihD/Mi. 
rates of incident Mi and ihD were estimated. hrs were 
modelled using multivariable cox proportional hazards 
regression accounting for potential confounders.
results ilD was independently associated with ihD (hr 
1.85, 95% ci 1.56 to 2.18) and Mi (hr 1.74, 95% ci 
1.44 to 2.11). in all disease categories, risk of both ihD 
and Mi peaked between ages 60 and 69 years, except 
for the risk of Mi in Ps which was greatest <50 years. 
Men with PF were at greatest risk of ihD, while women 
with PF were at greatest risk of Mi.
Conclusions ilD, particularly PF, is independently 
associated with Mi and ihD after adjustment for 
established cardiovascular risk factors. Our results 
suggest clinicians should prioritise targeted assessment 
of cardiovascular risk in patients with ilD, particularly 
those aged 60–69 years. Further research is needed 
to understand the impact of such an approach to risk 
management.
bACkgrOund
The interstitial lung diseases (ILDs) are a heterog-
enous group of diffuse parenchymal lung disor-
ders characterised by fibrotic and/or inflammatory 
changes to the interstitial lung tissue.1 2 The most 
common of these conditions is idiopathic pulmo-
nary fibrosis (PF), which affects between 14 and 63 
per 100 000 population in the USA, and between 
1.25 and 23.4 per 100 000 population in Europe.3 
It is considered progressive and fatal; however, 
the course of the disease is variable with evidence 
suggesting comorbidity burden contributes 
significantly to risk of disease progression and excess 
mortality.4 5 Pulmonary sarcoidosis (PS) has tradi-
tionally been considered a more benign condition; 
however, an increasing trend in rates of mortality 
and hospitalisation of patients with sarcoidosis has 
been reported, with comorbid conditions thought 
to play an important role in this.6
Ischaemic heart disease (IHD) is prevalent among 
patients with ILD with rates of IHD among patients 
with interstitial pulmonary fibrosis (IPF) reported 
to be as high as 68%.4 IHD is the second most 
common cause of death in patients with IPF, after 
IPF itself.7–9 The underlying pathogenesis of ILD 
and IHD share a number of pathophysiological 
mechanisms including oxidative stress, vascular 
endothelial injury and release of proinflamma-
tory cytokines associated with a hypercoagulable 
state and formation of microthrombi.10 11 Despite 
recognition of their coexistence, shared risk factors 
(RFs), the importance of burden of comorbidities 
in the disease course of ILD, and the availability of 
effective primary and secondary IHD prevention 
measures that could be considered to mitigate any 
increased risk of IHD in patients with ILD, research 
examining the risk of incident IHD in patients with 
ILD are few in number, small in terms of sample 
size and report lengths of follow- up potentially 
inadequate to detect the outcomes of interest.12–15
This study therefore aimed to investigate the risk 
of incident IHD and myocardial infarction (MI) in 
a large cohort of patients with ILD, compared with 
those without, using linked data from primary and 
secondary care.
MeThOds
data source and study population
The Clinical Practice Research Datalink (CPRD) is 
one of the largest databases of electronic primary 
care records in the world, covering approximately 
7% of the UK population, and is representative 
of the broader UK population. Practices record 
patient demographics, consultations, hospitalisa-
tions, specialist referrals, prescriptions, test results, 
immunisations and diagnoses. Clinical information 
is entered using Read codes, a standard clinical 
terminology system used in general practice in the 
UK. Prescriptions are recorded using Multilex (or 
British National Formulary) codes. The quality of 
the data is regulated by the Medicines and Health-
care Products Regulatory Authority and only used 
when it has reached a certain standard of quality. 
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High validity of diagnostic Read codes has been demonstrated 
within the CPRD.16 17 CPRD data can now be linked with 
Hospital Episode Statistics (HES), which has details of all NHS 
inpatient care, hospital outpatient visits and emergency hospital 
attendance in England. Data from private patients treated in 
NHS hospitals and care delivered by treatment centres funded 
by the NHS are also included. Demographic data, along with 
discharge diagnoses and procedures, are recorded using the 
International Classification of Diseases version 10 and Opera-
tion and Procedure Coding Supplement version 4, respectively, 
and are linked to primary care data by a trusted third- party using 
NHS number, date of birth and sex. The CPRD- HES linked data 
covers more than 3% of the total English population and are 
representative of the general UK population.18
ILD exposure was defined as a recorded diagnosis of PS or 
PF (including idiopathic PF, cryptogenic fibrosing alveolitis and 
idiopathic fibrosing alveolitis) in their general practice electronic 
health record (EHR) between 1998 and 2017 using Read codes 
(available at https://www. keele. ac. uk/ mrr). The date associated 
with the first- ever Read code for the conditions of interest was 
taken to be the date of diagnosis (‘Index date’). Each incident 
case was matched to five controls without a diagnosis of either 
condition on age (±5 years, sex, available follow- up time in 
CPRD (±3 years) and registered general practice. Unexposed 
patients were assigned the same index date as their matched 
ILD- exposed patient and for both, follow- up commenced from 
that index date. Those with a prior history of IHD (including 
coronary artery disease (CAD), angina and acute coronary 
syndrome) or MI, or less than 1 year of follow- up after the index 
date were excluded. Exposed and unexposed participants were 
required to be over age 18 years at diagnosis of ILD (or matched 
index date), have linkage to HES data to identify outcomes of 
interest, have no history of any of the outcomes of interest prior 
to the diagnosis of ILD and have 6- month up- to- standard data 
follow- up in CPRD.
The validity of diagnostic Read codes in CPRD for one of the 
rarer forms of inflammatory lung disease, cryptogenic fibrosing 
alveolitis, has been assessed by comparison with hospital docu-
mentation and was shown to be high with a positive predictive 
value of 95%.19
Outcome definition
The primary study outcomes were IHD (including CAD, angina 
and acute coronary syndrome) and MI identified using medical 
codes assigned by GPs, or in secondary care HES data (list of 
Read codes used to identify outcomes available at https://www. 
keele. ac. uk/ mrr). Validity of general practice diagnoses has been 
reported to be high, with a positive predictive of 85.3% for 
circulatory diseases,17 and 82%–92% for acute MI.17
Covariates
Potential confounders considered were body mass index 
(BMI), smoking status and alcohol consumption (yes, no, ex 
or unknown), hypertension, hyperlipidaemia, diabetes, chronic 
kidney disease, prescription for cardiovascular drugs (defined as 
at least 30 days supply of an antihypertensive, antiplatelet or 
lipid- lowering medication), reported family history of cardio-
vascular disease and socioeconomic status defined based on the 
area in which the general practice at which the patient was regis-
tered is located (quintiles by rank of Indices of Multiple Depriva-
tion).20 They were identified closest to the index date from both 
the primary care EHR and linked HES data.
statistical analysis
Absolute rates (ARs) of IHD and MI per 10 000 person- years 
(PY) and 95% CIs were calculated for cases and controls. Cox 
proportional hazards regression was used to calculate HRs 
adjusted for the stated confounding factors. Those with missing 
BMI data were categorised into a separate ‘missing’ category and 
included in the analysis, as there is evidence that in this data-
base, BMI data cannot be assumed to be missing completely at 
random, and therefore may not satisfy the ‘missing at random’ 
assumption required for multiple imputation.21 The propor-
tional hazards assumption was tested using Schoenfeld resid-
uals plot. All statistical analyses were performed using Stata 
V.15.1.This study was reviewed and approved by the CPRD’s 
in- house Independent Scientific Advisory Committee (ISAC) 
reference number: 15_214RA
As we have a matched sample, this introduces a bias that must 
be accounted for in the analysis stage. Matched subjects will have 
correlation (greater similarity) in outcomes than two randomly 
selected subjects. This is because their baseline covariates are 
more similar, and baseline covariates are related to outcomes. We 
must therefore account for the lack of independence in outcomes 
that have been induced by matching. Hence, to account for the 
matched nature of the sample, we use a robust variance esti-
mator that accounts for the clustering within matched sets.22
sensitivity analysis
Two sensitivity analyses were performed. First, analyses were 
repeated removing patients with a coded diagnosis of cardiac 
sarcoidosis during the time period of observation in order to 
understand the impact of sarcoidosis affecting the cardiac system 
on our findings. Second, analyses were repeated introducing 
number of GP consultations during the period of observation as 
a variable to investigate the potential impact of surveillance bias.
Patient and public involvement
Patients were involved in prioritising the research question but, 
due to the nature of the study using a database of electronic 
healthcare records, they were not involved further in the design, 
conduct or reporting of this work.
resulTs
basic characteristics
Data were analysed for 11 688 ILD- exposed participants, and 
56 884 unexposed matched controls, over a total of 349 067 PY. 
Table 1 presents the characteristics of participants.
Patients with PS were younger, had a lower burden of cardio-
vascular RF and longer median duration of follow- up than either 
patients with PF or controls.
Myocardial infarction
The AR of MI was highest in patients with PF (AR 72.57 (95% 
CI 62.95 to 83.65) per 10 000 PY). Rates of MI were lower in 
those exposed to PS than unexposed patients (16.01 (95% CI 
12.17 to 21.07) vs 32.26 (95% CI 30.26 to 34.39) per 10 000 
PY) (table 2).
Risk of MI compared with unexposed patients was similar 
between the ILD combined group patients and PF group (HR 
1.53 (95% CI 1.33 to 1.77 vs HR 1.58 (95%CI 1.35 to 1.85)). 
The PS group was not at increased risk of MI. While for men, 
risks of MI were similar across each of the disease categories, 
women with PF were at greatest risk of MI and greater than their 
male counterparts. In ILD and PF risk of MI peaked between 
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Table 1 Characteristics of participants
Ild
(n=11 688)
Ps
(n=4568)
PF
(n=7120)
non- Ild controls
(n=56 884)
Mean age (SD) 62.2 (16.8) 48.0 (12.9) 71.4 (11.9) 64.7 (16.3)
Male, n (%) 6291 (53.8) 2313 (50.6) 3978 (55.8) 31 854 (56.0)
Median follow- up, years (IQR) 3.8 (1.8–7.3) 6.1 (2.8–10.5) 3.0 (1.5–5.4) 4.0 (2.0–7.4)
Hypertension, n (%) 3577 (30.6) 752 (16.5) 2825 (39.7) 17 030 (29.9)
Hyperlipidaemia, n (%) 1461 (12.5) 311 (6.8) 1150 (16.2) 6533 (11.5)
Diabetes mellitus, n (%) 1344 (11.5) 345 (7.6) 999 (14.0) 4995 (8.8)
Chronic kidney disease, n (%) 1173 (10.0) 179 (3.9) 994 (14.0) 3998 (7.0)
BMI (kg/m2)*
  Normal (≥18.5 ≤24.9) 3430 (29.4) 1256 (27.5) 2174 (30.5) 16 983 (30.0)
  Underweight (<18.5) 289 (2.5) 63 (1.4) 226 (3.2) 1166 (2.1)
  Overweight (≥25.0 ≤29.9) 4081 (34.9) 1528 (33.5) 2553 (35.9) 17 768 (31.2)
  Obese (>30) 2890 (24.7) 1293 (28.3) 1597 (22.4) 10 682 (18.8)
  Not recorded 998 (8.5) 428 (9.4) 570 (8.0) 10 285 (18.1)
Alcohol consumption
  No 2286 (19.6) 836 (18.3) 1450 (20.4) 9284 (16.3)
  Yes 8058 (68.9) 3221 (70.5) 4837 (67.9) 36 533 (64.2)
  Ex 356 (3.05) 89 (1.9) 267 (3.8) 1395 (2.5)
  Not recorded 988 (8.45) 422 (9.2) 566 (7.9) 9672 (17.0)
Smoking history
  No 5867 (50.2) 3005 (65.8) 2862 (40.2) 27 406 (48.2)
  Yes 1453 (12.4) 518 (11.3) 935 (13.1) 9406 (16.5)
  Ex 4188 (35.8) 986 (21.6) 3202 (45.0) 14 579 (25.6)
  Not recorded 180 (1.5) 59 (1.3) 121 (1.7) 5493 (9.7)
Family history of CVD 2410 (20.6) 920 (20.1) 1490 (20.9) 10 545 (18.5)
Socioeconomic status (quintiles of Index of Multiple Deprivation)
  1 (least deprived) 1638 (24.7) 702 (15.4) 936 (13.1) 7548 (13.3)
  2 1535 (23.2) 611 (13.4) 924 (13.0) 7639 (13.4)
  3 1302 (19.7) 493 (10.8) 809 (11.4) 6689 (11.8)
  4 1203 (18.2) 482 (10.6) 721 (10.1) 5656 (9.9)
  5 (most deprived) 942 (14.2) 386 (8.5) 556 (7.8) 4475 (7.9)
Exposure to cardiovascular drugs
  Antihypertensive 3494 (29.9) 717 (15.7) 2777 (39.0) 13 594 (23.9)
  Antiplatelet 768 (6.6) 101 (2.2) 667 (9.4) 3160 (5.6)
  Lipid lowering 1071 (9.2) 235 (5.1) 836 (11.7) 4449 (7.8)
*WHO Classification of Obesity According to BMI.
BMI, body mass index; CVD, cardiovascular disease; ILD, inflammatory lung disease; PF, pulmonary fibrosis; PS, pulmonary sarcoidosis.
ages 60 years and 69 years; however, in PS the youngest cohort 
of patients (<50 years) were at greatest risk.
Ischaemic heart disease
The AR of IHD was also highest in patients with PF (102.61 
(95% CI 91.06 to 115.64) per 10 000 PY). Rates of IHD were 
also lower in those exposed to PS than unexposed patients 
(20.09 (95% CI 15.73 to 25.67) vs 39.71 (95% CI 37.49 to 
42.07) per 10 000 PY) (table 3).
ILD exposure was associated with a 59% increased risk of 
IHD compared with unexposed patients (HR 1.58, 95% CI 1.37 
to 1.83). Patients with PF were at greatest risk (HR 1.78, 95% CI 
1.51 to 2.09), while patients with PS were not at any increased 
risk of IHD.
Risk of IHD was greatest in men, while risk of MI was greatest 
in women (table 4; figure 1). Risk of both IHD and MI peaked in 
the 60–69 age group, with the exception of PS where risk of MI 
was greatest in patients <50 years (table 4; figure 2).
Results of the sensitivity analysis excluding patients with 
cardiac sarcoidosis did not reveal any material change in the 
findings (online supplementary table S1). The associations 
identified in the main analysis were strengthened in the sensi-
tivity analysis adjusting for number of GP consultations (online 
supplementary table S2).
COnClusIOn
Main findings
Both men and women with ILD were at increased risk of IHD and 
MI compared with unexposed controls. PF patients have a 2–3 
fold greater incidence of acute myocardial infarction (AMI) and 
IHD in younger age groups compared with PS and unexposed 
controls. Women with PF were at greatest risk of MI (approx-
imately 80% excess risk), while men with PF were at greatest 
risk of IHD (also approximately 80% excess risk). Women with 
PS were not at any increased risk of IHD or MI. Men with ILD 
overall experienced a slightly higher risk of IHD and MI to that in 
women. In all disease categories, risk of both IHD and MI peaked 
between ages 60 years and 69 years, except for the risk of MI in PS 
which was greatest in the youngest age group (<50 years).
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Table 2 Myocardial infarction incidence rates per 10 000 person- year of follow- up by exposure status
Variables
unexposed Ild combined Ps PF
n PY rate* (95% CI) n PY rate* (95% CI) n PY rate* (95% CI) n PY rate* (95% CI)
Overall 56 884 291 038 32.26 (30.26 to 
34.39)
11 688 58 029 41.53 (36.60 to 
47.12)
4568 31 846 16.01 (12.17 to 
21.07)
7120 26 183 72.57 (62.95 to 
83.65)
Sex
  Male 31 854 151 469 40.27 (37.20 to 
43.60)
6291 29 195 54.12 (46.31 to 
63.25)
2313 15 473 20.68 (14.63 to 
29.24)
3978 13 722 91.83 (77.11 to 
109.34)
  Female 25 030 139 569 23.57 (21.16 to 
26.26)
5397 28 835 28.78 (23.21 to 
35.69)
2255 16 373 11.60 (7.40 to 
18.19)
3142 12 462 51.36 (40.20 to 
65.62)
Age (years)
  <50 12 272 94 517 4.97 (3.74 to 
6.62)
3075 22 576 10.63 (7.13 to 
15.86)
2691 20 207 7.92 (4.85 to 
12.92)
384 2369 33.77 (16.89 to 
67.51)
  50–59 7460 48 505 16.29 (13.06 to 
20.31)
1759 10 830 27.70 (19.37 to 
39.62)
1047 7091 21.15 (12.75 to 
35.09)
712 3740 40.11 (24.18 to 
66.53)
  60–69 11 321 57.911 30.39 (26.22 to 
35.23)
2308 10 643 63.89 (50.38 to 
81.04)
568 3376 29.62 (15.94 to 
55.04)
1740 7267 79.81 (61.71 to 
103.24)
  70–79 15 392 60 347 64.63 (58.52 to 
71.37)
2759 9443 80.48 (64.27 to 
100.77)
210 1004 89.60 (46.62 to 
172.21)
2549 8439 79.39 (62.49 to 
100.87)
  >80 10 438 29 757 83.01 (73.27 to 
94.03)
1786 4536 94.79 (70.30 to 
127.81)
52 168 59.67 (8.41 to 
423.59)
1735 4369 96.13 (71.05 to 
130.09)
*Rate per 10 000 person- years.
ILD, inflammatory lung disease; N, number; PF, pulmonary fibrosis; PY, person- years.
Table 3 Ischaemic heart disease incidence rates per 10 000 person- year (PY) of follow- up by exposure status
Variables
unexposed Ild combined Ps PF
n PY rate* (95% CI) n PY rate* (95% CI) n PY rate* (95% CI) n PY rate* (95% CI)
Overall 56 884 291 098 39.71 (37.49 to 
42.07)
11 688 58 064 57.35 (51.51 to 
63.85)
4568 31 849 20.09 (15.73 to 
25.67)
7120 26 215 102.61 (91.06 to 
115.64)
Sex
  Male 31 854 151 493 52.74 (49.21 to 
56.53)
6291 29 209 78.06 (68.56 to 
88.88)
2313 15 471 20.68 (14.63 to 
29.25)
3978 13 737 142.68 (124.03 to 
164.12)
  Female 25 030 139 605 25.57 (23.05 to 
28.37)
5397 28 855 36.39 (30.05 to 
44.06)
2255 16 377 19.54 (13.82 to 
27.67)
3142 12 477 58.51 (46.51 to 
73.59)
Age (years)
  <50 12 272 94 514 6.35 (4.93 to 
8.18)
3075 22 579 9.74 (6.42 to 
14.80)
2691 20 210 7.42 (4.47 to 
12.31)
384 2369 29.55 (14.09 to 
61.98)
  50–59 7460 48 513 24.94 (20.87 to 
29.81)
1759 10 841 37.82 (27.85 to 
51.36)
1047 7098 29.59 (19.29 to 
45.38)
712 3740 53.43 (34.47 to 
82.82)
  60–69 11 321 57 927 50.06 (44.62 to 
56.17)
2308 10 638 98.70 (81.52 to 
119.51)
568 3367 62.37 (40.67 to 
95.66)
1740 7271 115.52 (93.28 to 
143.07)
  70–79 15 392 60 369 79.68 (72.86 to 
87.12)
2759 9460 130.03 (108.96 to 
155.16)
210 1006 59.61 (26.78 to 
132.69)
2549 8453 138.41 (115.47 to 
165.91)
  >80 10 438 29 774 68.52 (59.73 to 
78.59)
1786 4546 92.39 (68.28 to 
125.02)
52 168 59.56 (8.39 to 
422.79
1735 4377 93.65 (68.96 to 
127.19)
ILD, interstitial lung disease; PF, pulmonary fibrosis; PS, pulmonary sarcoidosis.
strengths of this study
This study is the first to report the risk of MI in ILD and to report 
risks of IHD and MI by age and gender, identifying women with 
PF and patients <50 years with PS to be at greatest risk of MI. 
This study is also the first to adjust for important factors such as 
deprivation. The use of GP electronic medical records that are 
kept contemporaneously limits the risk of recall or observer bias 
and allows a long duration of patient follow- up. In addition, our 
study used linked secondary care data, which have been shown 
to ascertain outcomes more robustly.23
However, the findings of this study should be interpreted with 
caution due to the risk of misclassification resulting from the use 
of EHRs, although the validity of certain forms of inflammatory 
lung disease, including IPF diagnosis has previously been exam-
ined in such databases and was found to be high.20 The risk of 
surveillance bias should also be considered as it is possible that 
patients with ILD see their GP more frequently or are investi-
gated in more detail than those in the general population that 
may lead to increased opportunities for detection of disease, 
although the findings of our sensitivity analysis would refute 
this. Finally, while we adjust for the presence of RFs such as 
hypertension, we do not adjust for their severity, and there may 
be a differential impact on risk across a range of blood pressure 
values.
Interpretation in the context of other studies
While other studies do not report risk of IHD by age and sex, 
our overall findings are in line with those of previously published 
studies reporting an increased risk of IHD in patients with 
ILD.9 12–16 24–26 Two smaller studies that examined this association 
in an alternative database of UK primary care EHRs (The Health 
Improvement Network) reported an increased incidence of CAD 
or angina associated with IPF. After adjustment for age, sex and 
smoking status, Hubbard et al12 reported a rate ratio of incident 
CAD in 920 patients with IPF compared with 3593 controls of 
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Table 4 Risk of ischaemic heart disease (IHD) and myocardial infarction (MI) by exposure status
Ihd MI
Male Female Male Female
hr (95% CI) hr (95% CI) hr (95% CI) hr (95% CI)
ILD 1.66 (1.40 to 1.98) 1.36 (1.03 to 1.79) 1.55 (1.31 to 1.84) 1.49 (1.16 to 1.91)
PS 1.13 (0.78 to 1.63) 0.88 (0.55 to 1.41) 1.55 (1.13 to 2.14) 0.89 (0.56 to 1.42)
PF 1.81 (1.50 to 2.18) 1.67 (1.22 to 2.30) 1.51 (1.24 to 1.83) 1.80 (1.36 to 2.38)
 Age (years)
Ihd (hr (95% CI)) MI (hr (95% CI))
Ild Ps PF Ild Ps PF
<50 1.61 (0.92 to 2.81) 1.49 (0.83 to 2.66) 1.89 (0.56 to 6.33) 1.72 (1.04 to 2.83) 1.83 (1.10 to 3.05) 0.87 (0.21 to 3.66)
50–59 1.16 (0.73 to 1.82) 0.75 (0.41 to 1.36) 2.05 (1.13 to 3.72) 1.48 (0.95 to 2.29) 1.35 (0.80 to 2.28) 1.47 (0.78 to 2.74)
60–69 1.92 (1.46 to 2.52) 0.88 (0.51 to 1.53) 2.40 (1.79 to 3.22) 1.79 (1.35 to 2.38) 0.62 (0.32 to 1.22) 2.35 (1.74 to 3.16)
70–79 1.71 (1.35 to 2.17) 0.81 (0.36 to 1.81) 1.84 (1.45 to 2.35) 1.77 (1.40 to 2.23) 1.35 (0.72 to 2.54) 1.79 (1.40 to 2.29)
>80 1.08 (0.73 to 1.61) 0.82 (0.11 to 6.18) 1.10 (0.73 to 1.64) 0.91 (0.64 to 1.28) 1.30 (0.38 to 4.39) 0.89 (0.62 to 1.27)
All analyses adjusted for CKD, HTN, DM, HLD, BMI, exposure to smoking and alcohol, IMD, family history of cardiovascular disease and exposure to antihypertensive, antiplatelet 
and lipid- lowering drugs.
BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; HLD, hyperlipidaemia; HR, adjusted HR; HTN, hypertension; ILD, inflammatory lung disease; IMD, Index 
of Multiple Deprivation; PF, pulmonary fibrosis; PS, pulmonary sarcoidosis.
Figure 1 Risk of IHD (A) and myocardial infarction (B) by gender 
and exposure status. IHD, ischaemic heart disease; ILD, interstitial lung 
disease; PF, pulmonary fibrosis; PS, pulmonary sarcoidosis.
Figure 2 Risk of IHD (A) and myocardial infarction (B) by age and 
exposure status. IHD, ischaemic heart disease; ILD, interstitial lung 
disease; PF, pulmonary fibrosis; PS, pulmonary sarcoidosis.
3.39 (95% CI 2.02 to 4.87), which is slightly higher than the 
rate ratio in this study of 2.39 (95% CI 2.11 to 2.70) but may 
reflect the wider range of cardiovascular RFs adjusted for in this 
study. Dalleywater et al reported a rate ratio of IHD 2.32 (95% 
CI 1.85 to 2.93) in 3211 participants with IPF compared with 
12 307 controls, after adjustment for hypertension, hypercho-
lesterolaemia, diabetes, smoking status and BMI, similar to the 
findings of this study.15 A further study of 406 Korean patients 
with IPF reported that the incidence of CAD was higher (6.8%) 
compared with controls (2.8%) with a relative risk of 1.92 (95% 
CI 1.08 to 3.43), also similar in magnitude to our findings.16 
Increased prevalence of angiographically determined CAD in 
patients with PF has also been reported, with an OR of 2.18 
for the presence of angiographic CAD in patients with fibrotic 
versus non- fibrotic lung disease.24 Significantly more CAD was 
reported in 49 patients with lung fibrosis (28.6%) compared 
with 51 with emphysema (9.8%, p=0.02 for difference) despite 
there being significantly more smokers in the emphysema group 
(98% vs 31%),25 and prevalence of CAD was higher in pretrans-
plant IPF patients (65.8%) than pretransplant chronic obstruc-
tive pulmonary disease patients (46.1%, p=0.03 for difference) 
independent of CAD RFs. IPF patients with severe CAD also had 
worse outcomes than controls with a similar disease burden in 
this study.26
In common with other studies, there was an increased prev-
alence of established cardiovascular RFs in our ILD and PF 
cohorts,15 and while we adjusted for the presence of these RFs, 
we could not adjust for their severity. It is therefore possible that 
this association reflects either less well controlled cardiovascular 
RFs in patients with ILD/PF or the presence of unmeasured 
novel cardiovascular RFs.
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key messages
What is already known on this subject?
 ► In common with other inflammatory diseases, such as 
rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE), interstitial lung disease (ILD) and ischaemic heart 
disease (IHD) share a number of pathophysiological 
mechanisms and common risk factors. However, unlike 
these other diseases, the risk of IHD in patients with ILD is 
poorly understood. This lack of data could be preventing 
patients with ILD who may benefit from screening for these 
cardiovascular diseases from receiving it, as patients with RA 
and SLE have.
What might this study add?
 ► This study is the first to report the risk of myocardial 
infarction (MI) in ILD and to report risks of IHD and MI by 
age and gender, identifying women with pulmonary fibrosis 
(PF) and patients <50 years with pulmonary sarcoidosis to be 
at greatest risk of MI. This study is also the first to adjust for 
important factors such as deprivation.
 ► This study demonstrates that the presence of PF provides 
independent information to the incident risk of MI/IHD on top 
of classical cardiovascular RFs.
how might this impact on clinical practice?
 ► The increase in risk of AMI/IHD associated with PF/ILD in 
this study exceeds that attributed to RA within the preferred 
model of newest iteration of the QRISK tool and in younger 
age groups also exceeds that attributed to SLE. It could 
therefore be argued that in common with recommendations 
for RA/SLE, clinicians should screen patients with ILD for IHD, 
and furthermore, ILD should be considered in future iterations 
of cardiovascular risk stratification tools.
It has also been suggested that the presence of a serious lung 
disease might distract medical attention from routine cardio-
vascular care and that either primary and secondary prevention 
interventions are neglected, or symptoms that might be sugges-
tive of cardiovascular disease are falsely attributed to the known 
respiratory condition.12
Several pathophysiological mechanisms may account for the 
association between ILD and CAD. Autoantibodies such as anti-
nuclear antibody and antiendothelial cell antibodies are known 
to circulate in higher concentrations in patients with IPF than 
the general population, and deposition of such autoantibodies 
in the endothelial cells of lung tissue may stimulate the release 
of proinflammatory cytokines and monocyte recruitment and 
activation.10 In addition, oxidative stress may play a role.11 This 
triggering of the inflammatory cascade has been hypothesised to 
cause endothelial injury or necrosis and is also associated with a 
hypercoagulable state, the formation of microthrombi and the 
activation of fibroblasts in common with mechanisms that have 
been implicated in IHD and MI.10 27 28 Patients with IPF have 
been reported to have an increased tendency to thromboembolic 
disease and to have higher factor VIII levels than the general 
population, with elevated factor VIII levels also associated with 
an increased risk of CAD.29
In common with other systemic inflammatory disorders, this 
study demonstrates that the presence of PF provides independent 
information to the incident risk of MI/IHD on top of classical 
cardiovascular RFs. This has led to both rheumatoid arthritis 
(RA) and systemic lupus erythematosus (SLE) being included 
in cardiovascular risk stratification tools.30 The increase in risk 
of AMI/IHD associated with PF/ILD in this study exceeds that 
attributed to RA within the preferred model of newest iteration 
of the QRISK tool (HR men 1.23 (95% CI 1.19 to 1.28); women 
1.24 (95% CI 1.20 to 1.27)) and in younger age groups also 
exceeds that attributed to SLE (HR men 1.55 (95% CI 1.15 to 
2.10); women 2.14 (95% CI 1.78 to 2.56)).30 It could therefore 
be argued that ILD should be considered in future iterations of 
cardiovascular risk stratification tools.
Conclusion
Our results enable clinicians to identify which cohorts of ILD 
patients are most at risk of IHD and MI and target their assess-
ment of cardiovascular risk appropriately. Our results also suggest 
that a more aggressive approach to primary prevention may be 
warranted in certain groups of ILD patients, for example, those 
<50 years old with PS. Further research is needed to understand 
the impact of such a stratified approach to risk management.
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